Investigations of the influence of an actual exposure on the in-vitro-activities and the inducibility of cytochrom P-450 dependent enzymes have not been described in the literature until now. First results gained from mitogen-stimulated lymphocytes of exposed and not-exposed individuals suggest such an influence of the given mixture of noxious agents on the basic deethylational ability of the examined cells acting in the sense of inhibition. Possible causes for this phenomenon are discussed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Optimization of Clozapine Treatment: Study of Variables Affecting Response in Uruguayan Patients With Schizophrenia.
J Clin Psychopharmacol
December 2024
Human Molecular Genetics Laboratory, Institut Pasteur de Montevideo.
Purpose/background: Clozapine is the recommended drug for treatment-resistant schizophrenia. Drug response could be affected by numerous factors such as age, sex, body mass index, co-medication, consumption of xanthine-containing beverages, smoking, and genetic variants of the enzymes involved in clozapine metabolism (CYP1A2, CYP3A4, and, to a lesser extent, CYP2C19 and CYP2D6). This study evaluated genetic and nongenetic variables that may affect clozapine plasma concentrations in Uruguayan patients with schizophrenia.
View Article and Find Full Text PDFAbsorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRAS inhibitor.
Cancer Chemother Pharmacol
December 2024
Clinical Pharmacology and Nonclinical Development, Mirati Therapeutics Inc., San Diego, CA, USA.
Objective: This study investigated absorption, metabolism, and excretion of adagrasib after a single oral 600 mg dose (1 µCi [C]-adagrasib) in 7 healthy subjects and compared the metabolite profile to the profile at steady-state in 4 patients dosed at 600 mg twice daily.
Methods: Plasma, urine, and feces were collected post [C]-adagrasib administration and total radioactivity and pooled sample metabolite profiles were determined. Adagrasib pharmacokinetics were determined in plasma and urine.
Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review.
Cells
November 2024
Independent Researcher, 108815 Moscow, Russia.
Background: Cytochromes P450 (CYPs) are heme-containing oxidoreductase enzymes with mono-oxygenase activity. Human CYPs catalyze the oxidation of a great variety of chemicals, including xenobiotics, steroid hormones, vitamins, bile acids, procarcinogens, and drugs.
Findings: In our review article, we discuss recent data evidencing that the same CYP isoform can be involved in both bioactivation and detoxification reactions and convert the same substrate to different products.
Harnessing Pharmacogenomics for Personalized Medicine: Tailoring Drug Therapy to Genetic Profiles.
Zhongguo Ying Yong Sheng Li Xue Za Zhi
December 2024
Maharaja Agrasen Himalayan Garhwal University, Pauri Garhwal, Uttarakhand, India, 246169.
This study means to investigate the capability of pharmacogenetics which can customize drug treatment through altered treatment of male genetic profiles. We finished hereditary profiling utilizing cutting edge sequencing (NGS) to figure out the key hereditary varieties that impact the medications metabolic adequacy and security. Patients were checked for a very long time to evaluate clinical results including ADRs and general wellness.
View Article and Find Full Text PDFPopulation pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.
Clin Transl Sci
December 2024
Quantitative Clinical Pharmacology Department, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.
Article Synopsis
- This study evaluated the pharmacokinetics (PK) of quizartinib and its metabolite AC886 in newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML) patients receiving standard chemotherapy, using data from the Phase 3 QuANTUM-First trial and earlier studies.
- The PK of quizartinib was modeled as a three-compartment system, while AC886 followed a two-compartment model, both showing significant variability among individuals.
- The research also identified the influence of CYP3A inhibitors on drug exposure, revealing a need for dose adjustments and noting differences in quizartinib exposure across treatment phases compared to previously studied patient groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!